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Objectives
• Revisit IMM
– What is the Integrated Medical Model?
– How should it be used?
• External Review Design and Make-up
• External Review Findings and Responses
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IMM in a Nutshell
• Platform to asses mission medical risk using 
proven risk assessment techniques.
• Platform for exploration of the medical kit trade 
space effects on risk. 
• Gives decision-makers a means to balance 
medical risk with limited resources. 
• Engineering teams with quantitative medical 
information to characterize risk.
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This is fundamentally about how the NASA Medical and 
Engineering communities communicate.
A Verifiable and Validatable Process
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• Considerations for age, sex, and mission duration
• Optimum medical system to minimizing risk 
• Estimate of functional impairment to the crew 
• Mission risk affected by medical system trades
Validation Against Real World Observations
• Model validation utilized real world system (RWS) observations 
from International Space Station (ISS) Expedition (Exp) 14 
through 39/40 
• IMM simulation for each expedition
– Assuming ISS med capabilities, crew specific parameters and duration
– Using data obtained from ISS missions and STS missions prior to referent
• Total number, type and outcomes compared to RWS
– RWS LOCL and EVAC set to zero
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Snapshot of results for RWS ISS 
missions: IMM generally over-
predicts by 3-4 medical events as 
indicated by regression intercept 
estimates and slope generally less 
than 1 (Considering IMM Condition 
List events only).
Individual Condition Counts
• 24 conditions failed to meet the performance characterization 
criteria 
• 17 over-predicted and 7 under-predicted the number of events
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Over-prediction
External Review & 
Findings
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Model and External Review
Monte Carlo Simulation: Typically ~100,000 trial simulations
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External Review Panel
ExMC convened an external review panel through 
the GSFC Systems Review Branch 
• Chair: Dr. Bryant Cramer (GSFC – Retired)
• Review Manager: Mr. Neil Martin (GSFC)
• Aerospace Medical : Dr. Jan Stepanek (Mayo Clinic)
• Epidemiologist: Dr. Guohua LI (Columbia University) 
• Chief Engineer /Software : Mr. Steve Scott (GSFC)
• Software: Mr. Robert Schweiss (GSFC)
• Biostatistics/Probability Theory : Dr. Nancy Lindsey (GSFC)
• Software/ Project Management : Mr. Dick Kauffman (Criterion systems)
• Computational Modeling : Dr. Gary Pradhan (Mayo Clinic)
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External Review Board
IMM External Review
From Nov 2015 to May 2016
• 2 Pre-Meeting Summaries : “Introduction to IMM” and “IMM Validation 
Strategies” 
• Board formally convened three times Dec 2015, Jan 2016, March/April 2016 
External Review Topics
• Model Concepts and Software and code standards (i.e. JPR- 7150.2B 
compliance)
• Input pedigree of incidence and outcomes information (NASA-STD-7009: 
Input Pedigree Credibility Factor)
• Model performance (NASA-STD-7009 Verification, Validation, Sensitivity, 
Operations, Use History) 
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Ensure internal processes for identifying, ranking quality, and including 
medical data with evidence-based rationale is appropriate to capture 
medical risk likelihood, medical information, and outcome uncertainty for 
the model application.
• Presented evidence related to data process and data capture
– A selection of 10 Clinical Findings Forms (CliFFs) summarizing the 
types of data and conditions used to inform IMM simulations
• Atrial Fibrillation
• Burns Secondary to Fire
• Decompression Sickness 
Secondary to EVA
• Dental Abscess
• Headache (Space 
Adaptation)
• Hip-Proximal Femur 
Fracture
• Eye Chemical Burn
• Stroke
• Sepsis
• Urinary Retention (Space 
Adaptation)
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Input Pedigree
Summary Review Comments
Board identified strengths: 
• The concept of the IMM is scientifically sound and it works.
• The IMM represents a necessary, comprehensive approach to identifying medical 
and environmental risks facing astronauts in long duration missions.
• Because it integrates with the Exploration Probabilistic Risk Assessment 
(ExPRAT), the IMM has become an excellent tool through which engineers and 
physicians can better communicate with each other by speaking a common risk 
assessment language.
• The validation approach is sound and the use of actual space medical data is 
logical and compelling.
• IMM statistical methods for processing and analyzing the input data, performing 
simulations, and generating and presenting quantitative outputs are scientifically 
sound.
• The IMM validation approach is sound and the match between the IMM and the real 
world system is good.
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Summary Review Comments cont.
Board identified issues:
• Need for stronger software engineering involvement particularly in terms of quality 
assurance.
• Accuracy concerns regarding the CliFFs; the Board found a numbers of errors 
necessitating a robust reviews of all remaining CliFFs.
• Need for a sustainable approach to augment, peer review, and maintain the CliFFs.
• Organizational issues:
– Physical separation of Project Management from Development Team presents a challenge.
– Evolutionary path for IMM insufficiently defined.
– Need for a well-developed Operations Concept.
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RFA Summary
• Total of 28 RFAs and 6 advisories submitted
• Project combined 8 of the RFAs for consolidated 
responses 
– New total : 24 RFAs
• RFA closure summary
– All Submitted for closure as of 11/15/2016
• 23 – Evidence or plan to secure evidence supplied as a 
response
• 1 – Element and project decision not to pursue a response at 
this time
– Closure acceptance received 12/2016
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- A summary of each IMM Project response is provided in the backup slides
RFA Closure Schedule
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RFA# W1 W2 W3 W4 W1 W2 W3 W4 W1 W2 W3 W4 W1 W2 W3 W4 W1 W2 W3 W4 W1 W2 W3 W4 W1 W2 W3 W4 W1 W2 W3 W4 W1 W2 W3 W4 W1 W2 W3 W4 W1 W2 W3 W4 W1 W2 W3 W4 W1 W2 W3 W4
01 01   
01 02   
01 03   
01 04   
01 05   
01 06   
01 07   
01 08   
02 01   
02 02   
02 03   
02 04   
02 05   
02 06   
02 07   
02 08   ?
02 09   
02 10   
02 11   
02 12   
03 01   
03 02   
03 03   M
03 04   
03 07   
03 09   
 RFA Received  Submit for Closure  Closure Date  Anticipated Closure Date ? To Be Determined
Response Development Author Review M Merge With Existing RFA
Dec Jan Feb March DecNovAug Sept OctApril May June July
Summary of Significant RFA Closure Activities
• Code modifications were performed to reduce run times by 70%. 
• Adjustments to reviewed condition information
– Minor typographical updates to DCS and Stroke CLIFF. 
– Updated data after addressing board suggestions and source data from the primary references.
• Dental Abscess CLIFF – reevaluation of source data categorization of medical condition.
• Space Adaption headache leading to evacuation reduced from 1.5% max to 0% max.
• Eye Chemical Burn updated rationale.
• Sepsis Updated rationale.
• Developed survey document guidelines for improved configuration management of 
clinical data identification.
• Performed a calibration of CHI using the RWS and iMED data information  (Accepted for 
Closure RFA 3.02).
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IMM Project Planned Pre- Delivery Activities
• Updated NASA-7009 Credibility Thresholds Per accepted RFA plan 
(12/1/2016 – 3/7/2017)
• Complete STS RWS validation activity (12/1/2016 – 6/1/2017)
• Complete iMED 6.5  (12/5/2016 – 2/10/2017)
• Add RWS data to iMED 6.5 (3/31/2107 – 4/21/2017)
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Conclusions
• IMM is a tool intended to help mission planners make 
decisions regarding medical risk and supplies.
• It is intended to pull in data and experience to provide the 
best current information to inform medical resource 
planning.
• Outcomes of the IMM 4.0 review
– Definite need for the model of this type  - validation testing illustrates its utility
– Concerns expressed that the medical condition information requires further 
review
• Forward work plan toward transition to customer baselined
– Final negotiation of ConOps plan with CHS
– RWS validation for STS and RWS data integrated into iMED
– Completion planned NLT 5/30/2017
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Backup Slides
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Forward Work
• Obtain Feedback from Medical Operations that the validation 
activity of IMM has appropriate clinical context
– (Provided guidance) Requires a formal flight surgeon participant review of IMM 
validation activities 
• Develop a Process and Review Remaining CliFFs
– (Completed as part of another RFA) Develop formal process for surveying, 
identifying, implementing and routine maintenance of IMM source data
– (Completed) All CLIFF references double checked and improved CLIFF report 
generation implemented within iMED
– (Deferred) Develop/Negotiate requirements, review criteria and formulate 
review plan guidance 
– (Deferred) Implementation to follow plan development
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Board Findings: Recommendations 
Recommendation 
Number
Recommendation ExMC Response Subject
1 To achieve operational status, the IMM Team should add a 
Software Engineer and a software architect with experience in 
developing software as outlined in JSC 7150.2 and Capability 
Maturity Model Integration (CMMI) with a  one year goal of 
achieving a CMMI Level 2.  CMMI Level 3 as a three-year goal.
Recommendation noted and will be 
forwarded to the operator; further 
development beyond delivered S/W 
is at the discretion of Operator.  SQA 
processes adhere to 7150.2 
requirements
S/W 
Maturity
2 Implement the credible solutions developed in response to RFA 
2.07 to improve document management, configuration 
management, and verification (of medical conditons data).
Recommendation noted.  CM
processes of the iMED database 
implemented by 2/2017.  Guidance 
on maintenance and survey 
document content to be provided to 
Operator at delivery. 
CM
3 The remaining CliFFs should be meticulously reviewed. The 
Project does not plan to undertake a comprehensive 
review. The Board recommends that JSC reconsider this 
decision at the earliest opportunity.
Recommendation noted will be 
passed on to Operator; decision on 
further CLiFFs review is discretion of 
the Operator
CliFFs
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Recommendations and Conclusions paraphrased from original Text.  Original Text 
presented in backup slides
Board Findings: Recommendations cont.
Recommendation 
Number
Recommendation ExMC Response Subject
4 Recommend the development of a rigorous, scientifically 
sound, plan for long term sustainment of the CliFFs through 
systematic, periodic reviews of the terrestrial medical 
literature and space-based medical data while utilizing the
professional services of a medical librarian.
Recommendation noted will be passed 
on to Operator.  Operator to be provided 
guidance on prioritization, process and 
frequency of  medical data review within 
the CONOPS. Decision on iMED data 
sustainment is discretion of the 
Operator. 
CliFFs
5 Complete the current CONOPS and a compatible plan for an 
ORR so that a reviewer can readily see that in passing the 
ORR, the IMM Project and IMM Version 4.0 can successfully 
execute the CONOPS. 
Agree with recommendation. A Draft 
CONOPS will be delivered to operator, 
however some decisions and finalization 
of the CONOPS is discretion of the 
Operator as is the decision to proceed 
to ORR
ConOps
6 Address the Use History in the CONOPS, review the 
managerial processes in the CONOPS to address the Model 
& Simulation Management, and consider reducing the 
threshold of Input Pedigree from 3 to 2. 
CONOPS contains detail examples of 
IMM 3.0 use history.  Management 
process of the operation of the IMM is at 
the Operator discretion.  Reassessment 
of pedigree score planned by 1/2017.
ConOps
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Recommendations and Conclusions paraphrased from original Text.  Original Text 
presented in backup slides
Board Findings: Conclusions
Conclusion 
Number
Title Conclusion ExMC Response Subject
C1 Assess the 
development of 
IMM Version 
4.0. 
IMM Version 4.0 needs more robust managerial 
processes in requirements development, 
requirements management, documentation 
management, configuration control, and software
verification. This is particularly evident in software 
development.
Conclusion noted and will be forwarded to the 
operator; project staffing and future 
development is at the discretion of Operator 
(See R1). Current project team will implement 
board recommended code changes with SQE 
oversight prior to delivery to the Operator. 
S/W 
Maturity
C2 Assess the 
accuracy and 
adequacy of 
medical baseline 
data 
incorporated in 
the Clinical 
Findings Forms 
(CliFFs) 
Due to the shortcomings found in the ten CliFFs
that were reviewed, the Board recommends that 
the remaining CliFFs be meticulously reviewed 
and a long-term process must be established to 
sustain and evolve the CliFFs. The CIiFFs are the 
foundation of IMM and the use of the IMM will 
never be widely accepted until the CliFFs are fully 
trusted. 
Conclusion noted will be passed on to Operator; 
decision on further CLiFF review is discretion of 
the Operator (See R 3, 4)
CliFFs
C3 Assess the 
readiness of 
IMM Version 4.0 
for operations
IMM Version 4.0 is not yet ready for 
operations. Readiness requires the completion of 
the CONOPS, passing an Operational Readiness 
Review and completing a comprehensive review 
of the CliFFs.
A Draft ConOps will be delivered to operator, 
however some decisions and finalization of the 
ConOps is discretion of the Operator as is the 
decision to proceed to ORR (See R5, 6). The 
board's reservation to deploying the current 
iMED without complete CliFF review will be 
communicated to the Operator as well as RWS 
data to support a decision about deployment 
(and at what level)
ConOps
1Recommendations and Conclusions paraphrased from original Text.  Original Text 
presented in backup slides
IMM Core Application Questions
• What medical conditions will occur most?
• What medical resources will be used?
• What is the probability of evacuation?
• What is the probability of loss of crew life?
• What is the range of crew impairment?
• What are the optimal medical resources?
25
These are the types of questions that helped create the model
Integrated Medical Model (IMM) Project History
Conceived in 2005, as a means to inform medical resource planning  and 
quantify aspects of mission medical risk for CHS and ExMC
– Developed by ExMC and operated by CHS
The intent was to utilize available space flight community knowledge base as an 
integral part of the simulation environment
– Sources:  U.S. astronaut data
– analog and general population information with appropriate quality and applicability to space 
flight concepts
Not envisioned to be
– A diagnosis tool or definitive assessment of medical treatment
– A means of assessing countermeasure efficacy or performance decrement 
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We wanted to know what was likely to happen in a mission.
We wanted to know how to best design a medical kit.
iMed Database
CliFF*
Incidence 
Data
Treatment & Outcomes
Resources
Citations, Levels 
of Evidence & 
Quality 
*Clinical Findings Form
27
li *CliFF*li *
IMM Evidence Database
• Lifetime Surveillance of Astronaut Health (LSAH)
• ISS Expeditions 1 thru 13 (2006)*
• STS-01 thru STS-114 (2005)
• Apollo, Skylab, Mir (U.S. crew only)
• Analog, terrestrial data
• Bayesian Analyses
• Independent predictive models
• Flight Surgeon Delphi Study
• Russian medical data not used
• Sizeable U.S. crew data update received from LSAH in the past 
few weeks. This will be added to the model.
* More current data used for Visual Impairment Intracranial Pressure (VIIP)
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What does EVAC mean?
• EVAC in the context of the ISS 
• EVAC if any criteria are met:
– potential LOCL
– potential significant permanent impairment
– potential intractable pain
– No other assumptions are made
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iMED
Internal 
Verification 
Internal 
Validation 
External 
Review 
External 
Review 
Disposition
IMM
Internal 
Verification 
Internal 
Validation 
External 
Review 
External 
Review 
Disposition
Verification, Validation & Credibility (VV&C)
• Version 3.0 in use since 2011
• Following NASA-Standard-7009
• Internal VV&C v4.0: 
– 7150.2 compliance review
– Testing with specific DRM challenges
– Assess face validation of performance 
capabilities
– Quantitative comparison to real world 
system and LSAH data pool (shuttle and 
ISS)
• External VV&C v4.0:
– SME review external to lead center (JSC)
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Inclusion of Timeline in 4.0
31
EVA
DCS?
SAS
Headache
SAS
3.0
4.0
Out of Tylenol
Headache
Use Ibuprofen!
Out of Tylenol Untreated
EVA DCS?
Launch Landing
How can it be used for operations?
• Scope
– Forecasts medical outcomes for in-flight operations 
only
– Forecasts medical impacts to mission
– Does not assess long-term or chronic post-mission 
medical consequences
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IMM addresses in-flight risk using ISS information as a 
stepping stone
Algorithm:  Maximize or minimize CHI, Evac, LOCL by 
changing your resources (what kit has the best CHI?)
How can CHS, HRP and ExMC use IMM?
• Which science and technology investments 
decrease crew and/or mission risk within vehicle 
resource constraints? 
• Which countermeasures have the greatest 
influence on in-flight crew and/or mission risk? 
Ref: IMM Conceptual Model Document
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What is the current state of IMM?
• Version 3.0 has been used for operational questions to this 
point.
• Version 4.0
– Internal Validation, Verification and Certification finished October 
2015.
– Delivery is targeting March 2016 (flexible).
– External Review (external to JSC and GRC) has been assembled and 
is proceeding.
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External Review of IMM v4.0
Review Type Conent
IMM software and code 
verification review (JPR 7150.2)
Dec 15-17, 2015
Ensure IMM satisfies requirements set out in JPR 7150.2.  These 
include compliance review, including black and white box testing, code 
verification.  Review products include a report with request for actions 
(RFAs)
Model Input Pedigree (iMED data):
Process Review (required by 
7009)
Jan 28-29, 2016
Ensure internal processes for identifying, ranking quality, and including 
medical data with evidence-based rationale in iMED is appropriate to 
capture medical risk likelihood, medical information, and outcome 
uncertainty for the model application. Insure current data in model is of 
sufficient pedigree for the model’s intended use. 
Review products: Summary report on the review outcomes including a 
prioritized list of RFA’s 
End-to-end review (required by 
7009 and 8900)
Feb 24-25, 2016
Perform thorough review of the model application and VV&C efforts to 
assess model performance meet functional requirements in the in area 
of application. This review addresses documented performance and 
VV&C efforts and could include independent testing of the model  
Review Products:  Summary report of the panel findings and a 
prioritized list of RFAs
ExMC Project Scientist convenes these reviews
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Status of Review
• Panel has been set
– Bryant Cramer  - Chair 
– Neil Martin  - Review Manager  GSFC
– Jan Stepanek - Aerospace Medicine  Mayo Clinic
– Guohua LI - Epidemiologist  Columbia University
– Steve Scott - Chief Engineer/Software - GSFC
– Robert Schweiss - Software – GSFC
– Nancy Lindsey - Biostatistics/Probability Theory - NASA
– Dick Kauffman – Software – Criterion Systems
– Gary Pradhan – Modeling Mayo Clinic
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IMM 7009 Review materials highlights
• Verification
– Unit testing for numerical accuracy, in combination with the 7150.2 req.
• Validation and Results Uncertainty
– Evaluation of model performance with respect to Clinical SME experience
• Face Validation
– Comparison to a Real World System : ISS (and STS if requested by panel) 
• Qualitative – RWS conditions rates and ranked resource types
• Quantitative – Conditions and outcomes
• Input Pedigree
– All Clinical Findings Reports for all 100 conditions in IMM – Details incidence, outcomes and resources
• Results Robustness
– Formal Sensitivity Analysis on conditions vs. outcomes using two techniques
• Use History
– Utilization of IMM v.3.0 (v4.0 technically has zero use history unless it can be deemed to encompass 
IMM v3.0)
• M&S Management
– Project and operation plans and schedules
• People Qualifications
– Training requirements, education and experience information (similar to a NIH proposal would require) 
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Review of software and code verification 
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Ensure the elements of IMM satisfy requirements set out in JPR 
7150.2B.  These include compliance review, black and white box 
testing, and code verification
• Presented evidence 
– IMM development concept and early concept of operations 
– Functional requirements compliance
– Derived software requirements compliance
• IMM, iMED database and tool for optimization of medical capabilities
– Compliance with standards JPR 7150.2B 
• Software assurance plan and Software classification review
– Introduction to model and simulation VV&C plan and NASA-STD-7009 
compliance
• Use History (v3.0), Project Management and Personnel 
Review of Model Performance : Verification, 
Validation, Sensitivity and Operations
Review of the model application and VV&C efforts to assess model 
performance in meeting functional requirements and adherence to 
NASA-STD-7009
• Presented evidence 
– Acquisition and processing of real world system (RWS) observed data
– Qualitative and Quantitative comparison of IMM performance versus RWS
– Uncertainty and sensitivity analysis for ISS class missions  
– Briefing from customer on use history and future ops concepts
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Snapshot of results for RWS ISS 
missions: IMM generally over-
predicts by 3-4 medical events as 
indicated by regression intercept 
estimates and slope generally less 
than 1 (Considering IMM Condition 
List  events only)
Levels of Evidence
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Space Flight Data
Anecdotal 
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Validated 
Models
AMA 
Impairment 
Guides
Clinical 
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3
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4
IMM Contacts
ExMC - IMM Project / Technical Management
Project Manager (GRC) Technical Director (GRC)
DeVon Griffin Jerry Myers
Devon.w.griffin@nasa.gov jerry.g.myers@nasa.gov
Integration Lead (JSC)                SSC Project Manager (WYLE)
Kerry McGuire Yamil Garcia
kerry.m.mcguire@nasa.gov Yamil.garcia@nasa.gov
Lead Team (SSC, Wyle)
Lynn Boley
Alexandra Keenan
Eric Kerstman
David Reyes
Lynn Saile
Marlei Walton
Millennia Young
Support Team (GRC)
Debra Goodenow
Donald Jaworske
IMM Development Team
Diagnosis and 
Treatment of Medical 
Conditions
Functional Impairments
ISS Medical System 
Resources
Risks due to 
Extravehicular Activities 
(EVAs)
Crew Member Attributes
Mission Duration and 
Profile
Medical Condition 
Incidence Data
Medical Resource 
Attributes
Clinical Outcomes and 
Mission Impact
What should be in the 
Exploration Medical Kit?
What is the likelihood of a 
medical evacuation?
What medical devices should 
we have on ISS?
What is the risk of Loss of 
Crew Life due to illness on 
ISS?
Without IMM
Flight Surgeon
??
?
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How does it work?
43
• Crew composition
• Crew size
• Gender
• # crowns
• Mission duration
• CAC score
• Prior abdominal surgery
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• Crew Health Index (CHI)
• LOCL (Loss of Crew Life)
• EVAC (Evacuation)
• Probability of occurrence 
for a condition(s)
• Best or worst case
• Optimized resources 
associated with above
IMM
Inputs Outputs
Typically runs 10,000 or 100,000 simulations using Monte 
Carlo techniques to Explore the parameter range
IMM Methodology
Best-case 
resources 
available?
Worst-case 
resources 
available?
Treated case: 
Decrement 
medical resources
Untreated Case
Treated case: 
Decrement 
medical resources
Untreated        
Worst- Case
Calculate End States:
• EVAC
• LOCL
• QTL
• Resource Utilization 
(how many bandaids?)
• Type and number of 
medical events
Best-case Scenario
Worst-case Scenario
Yes
Yes
No
No
Medical Event
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The IMM Medical Conditions**
1. Abdominal Injury  
2. Abdominal Wall Hernia  
3. Abnormal Uterine Bleeding  
4. Acute Arthritis  
5. Acute Cholecystitis / Biliary 
Colic  
6. Acute Compartment 
Syndrome  
7. Acute Diverticulitis  
8. Acute Closed-Angle 
Glaucoma  
9. Acute Pancreatitis  
10. Acute Prostatitis  
11. Acute Radiation Syndrome  
12. Acute Sinusitis  
13. Allergic Reaction (mild to 
moderate)  
14. Altitude Sickness  
15. Angina/ Myocardial 
Infarction
16. Anaphylaxis  
17. Ankle Sprain/Strain  
18. Anxiety  
19. Appendicitis  
20. Atrial Fibrillation/ Flutter  
21. Back Sprain/Strain  
22. Back Pain (SA)  
23. Barotrauma (sinus block)  
24. Behavioral Emergency    
25. Burns secondary to Fire  
26. Cardiogenic Shock secondary 
to Infarction  
27. Chest Injury  
28. Choking/Obstructed Airway  
29. Constipation (SA)  
30. Decompression Sickness 
Secondary to EVA  
31. Dental : Exposed Pulp  
32. Dental Caries  
33. Dental: Abscess  
34. Dental: Avulsion (Tooth Loss) 
35. Dental: Crown Loss  
36. Dental: Filling Loss  
37. Dental: Toothache  
38. Depression  
39. Diarrhea  
40. Elbow Dislocation  
41. Elbow Sprain/Strain  
42. Eye Irritation/Abrasion
43. Eye Chemical Burn  
44. Eye Corneal Ulcer 
45. Eye Infection   
46. Eye Penetration (foreign body)  
47. Finger Dislocation 
48. Fingernail Delamination (2º 
EVA) 
49. Gastroenteritis  
50. Head Injury  
51. Headache (CO2 
induced)  
52. Headache (Late)  
53. Headache (SA)  
54. Hearing Loss  
55. Hemorrhoids  
56. Herpes Zoster
57. Hip Sprain/Strain  
58. Hip/Proximal Femur 
Fracture  
59. Hypertension  
60. Indigestion  
61. Influenza  
62. Insomnia (SA)  
63. Knee Sprain/Strain  
64. Late Insomnia  
65. Lower Extremity Stress 
Fracture  
66. Lumbar Spine Fracture  
67. Medication Overdose / 
Reaction  
68. Mouth Ulcer   
69. Nasal Congestion (SA)  
70. Nephrolithiasis  
71. Neurogenic Shock  
72. Nose bleed (SA)  
73. Otitis Externa
74. Otitis Media  
75. Paresthesias (2º EVA)    
76. Pharyngitis 
77. Respiratory Infection 
78. Retinal Detachment  
79. Seizures  
80. Sepsis  
81. Shoulder Dislocation  
82. Shoulder Sprain/Strain  
83. Skin Abrasion  
84. Skin Infection  
85. Skin Laceration  
86. Skin Rash  
87. Small Bowel Obstruction  
88. Smoke Inhalation  
89. Space Motion Sickness (SA)  
90. Stroke (CVA)
91. Sudden Cardiac Arrest  
92. Toxic Exposure: Ammonia  
93. Traumatic Hypovolemic Shock  
94. Urinary Incontinence (SA)  
95. Urinary Retention (SA)  
96. Urinary Tract Infection  
97. Vaginal Yeast Infection  
98. VIIIP – Visual Impairment/ 
Increased Intracranial 
Pressure (SA)  
99. Wrist Fracture  
100.Wrist Sprain/Strain
SA = Space Adaptation        **47 conditions have occurred inflight, 53 others considered possible 46
The IMM Medical Conditions
SKIN
Burns secondary to Fire
Skin Abrasion
Skin Laceration
EYES
Acute Angle-Closure Glaucoma   
Eye Corneal Ulcer
Eye Infection
Retinal Detachment
Eye Abrasion
Eye Chemical Burn
Eye Penetration
EARS, NOSE, THROAT
Barotrauma (Ear/Sinus Block)
Nasal Congestion (SA)
Nose Bleed (space adaptation)
Acute Sinusitis
Hearing Loss
Otitis Externa
Otitis Media
Pharyngitis
DENTAL
Abscess
Caries
Exposed Pulp
Tooth Loss
Crown Loss
Filling Loss
CARDIOVASCULAR
Angina/Myocardial Infarction
Atrial Fibrillation / Atrial Flutter
Cardiogenic Shock secondary to Myocardial 
Infarction
Hypertension
Sudden Cardiac Arrest
Traumatic Hypovolemic Shock
GASTROINTESTINAL
Constipation (space adaptation)
Abdominal Injury
Acute Cholecystitis/Biliary Colic Acute 
Diverticulitis
Acute Pancreatitis
Appendicitis
Diarrhea
Gastroenteritis
Hemorrhoids
Indigestion
Small Bowel Obstruction
LUNG
Choking/Obstructed Airway
Respiratory Infection
Toxic Exposure:  Ammonia
Smoke Inhalation
Chest Injury
IMMUNE
Allergic Reaction (mild to moderate)
Anaphylaxis
Skin Rash
Medication Overdose/Adverse Reaction
NEUROLOGIC
Space Motion Sickness (Space Adaptation)
Head Injury
Seizures
Headache (Late)
Stroke (cerebrovascular accident)
Paresthesia Secondary to Extravehicular 
Activity
Headache (Space Adaptation) Neurogenic 
Shock
VIIP (Space Adaptation)
MUSKULOSKELETAL
Back Pain (Space Adaptation)
Abdominal Wall Hernia
Acute Arthritis
Back Sprain/Strain
Ankle Sprain/Strain
Elbow Dislocation
Elbow Sprain/Strain
Finger Dislocation
Fingernail Delamination Secondary to 
Extravehicular Activity
Hip Sprain/Strain
Hip/Proximal Femur Fracture
Knee Sprain/Strain
Lower Extremity (LE) Stress fracture
Lumbar Spine Fracture
Shoulder Dislocation
Shoulder Sprain/Strain
Acute Compartment Syndrome
Neck Sprain/Strain
Wrist Sprain/Strain
Wrist Fracture
PSYCHIATRIC
Insomnia (Space Adaptation)
Sleep Disorder
Anxiety
Behavioral Emergency
Depression
GENITOURINARY
Abnormal Uterine Bleeding
Acute Prostatitis
Nephrolithiasis
Urinary Incontinence (space 
adaptation)
Urinary Retention (space adaptation)
Vaginal Yeast Infection
INFECTION
Herpes Zoster Reactivation (shingles)
Influenza
Mouth Ulcer
Sepsis
Skin Infection
Urinary Tract Infection
ENVIRONMENT
Acute Radiation Syndrome
Altitude Sickness
Decompression Sickness Secondary 
to Extravehicular Activity
Headache (CO2)
47 conditions have occurred inflight, 53 others considered possible
Definitions of Calculated End States
Mission-level Outputs:
• Probability of (Consideration of) evacuation (EVAC)
• Proportion of simulated missions with one or more cases where 
evacuations considered for medical events
• Confidence limits are estimated
• Probability of loss of crew life (LOCL)
• Proportion of simulated missions with one or more loss of crew life
• Confidence limits are estimated
• Quality Time Lost (QTL)
• Sum (Functional Impairment x Duration) for all conditions that 
occur during a mission
• Resources used to treat these conditions
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Assumptions and Limitations addressed with 
IMM 4.0
Assumption or Limitation Addressed
in IMM v#
1 Baselined to ISS environment and ISS NASA medical system
2 No timeline 4.0
3 Medical conditions occur in pre-specified order 4.0
4 Full treatment at time of medical event occurrence 4.0
5 No correlation of medical conditions to crew activities 
6 No correlation of medical conditions between crew members
7 All crew members have essentially equal incidence for all medical conditions 4.0
8 No partial or alternative treatment 4.0
9 CMO time not accounted for
10 Diagnosis and treatment of medical conditions is 100 percent accurate
11 All pharmaceuticals are 100 percent effective
12 All medical equipment is 100 percent reliable
13 All exercise equipment is 100 percent reliable
14 Unlimited vehicle resources
15 No restocking of medical kit
16 No IMAK
Assumptions and Limitations
* Currently operating v3.0. In 2017 v4.1 will be operational.
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IMM Operational Version
• V3.0 Operational since 2011
• V4.1 Expected to be operational in May 2017.
Upgrades in V4.1
• Timeline – In addition to generating if conditions occur, IMM v4.0 
generates when conditions occur.
• Partial Treatment – IMM v4.0 gives partial credit for partial 
treatment in generating the outcomes of a condition.
• Alternative Drug – If a primary drug required for treatment is not 
available, IMM v4.1 searches for medically appropriate substitutes.
Usage of IMM
• Made via requests for information through CHS
• Operational Team works to insure the model scenario is tailored to 
your needs
• Due to review process the turn around time is ~8-12 weeks. 
IMM Operational
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Service Requests
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Requestor Question IMM Analysis
SD2 Requirement for Oxygen / 
Ventilator for Commercial 
Crew Vehicles?
Probability of  Oxygen / 
Ventilator use for ISS DRM (S-
20130607-100)
SD2 Is 4-orbit Soyuz docking 
to ISS safe?
Probability of SMS during 
docking to ISS (D-20130425-
91)
SK Which medications should be 
tested for stability?
Most frequently used
medications for Mars DRM (S-
20140306-145)
HMTA Loss of Crew Life (LOCL) 
Analysis
Probability of medical LOCL for 
EM-2 DRM (S-20130509-94)
ISS Program Medical Inputs to ISS PRA Probability of medical EVAC 
and LOCL for ISS DRM (D-
20101201-39)
Final Thought
Essentially, all models are wrong, but 
some are useful
George Box (1987); Professor Emeritus of Statistics at the  University of 
Wisconsin
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After Delivery - Communications Planning 
• Coordinated with CHS on ~6 publications for IMM, its components, or its application 
in the decision making process
– Real World System Validation (scheduled out to 8/2017)
– One and Two Factor Optimization of Space Flight Medical Resources
– Development and Application of Utility Metrics for Space Flight Risk Assessment
– 3 Application Case Studies
• Optional Tech Memos
– Medical Data Survey and Review
– Medical Data Processing and Maintenance
• Budget for contributing to the publications
– Current understanding is CHS will cover contractor efforts 
– CS estimate is 0.1  - 0.2 FTE, contributing to 3 of the publications 
1
Validation Of Model
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Why did we start building this model?
• Originally an Engineering attempt to use a 
Probabilistic Risk Analysis model that did not rely 
on a strong medical evidence base drove the 
development.
• Engineering teams need quantitative medical 
information to characterize risk.
• Medical SMEs did not have the capability to 
provide this.  
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This is fundamentally about how the NASA Medical and 
Engineering communities communicate.
Medical Condition 
Diagnosis and 
Treatment Data
Medical Condition 
Impairment and 
Outcomes Data
ISS Medical System 
Resources
Risks due to 
Extravehicular Activities 
(EVAs)
Crew Composition and 
Attributes
Mission Duration and 
Profile
Medical Condition 
Incidence Data
Clinical Outcomes and 
Mission Impact
What medications should be 
supplied?
What is the likelihood of a 
medical evacuation?
What medical devices should 
we have on ISS?
What is the risk of Loss of 
Crew Life due to illness on 
ISS?
What need does it fill?
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Medical 
Evidence 
Base
Individual Condition Counts
15 conditions met the performance characterization criteria
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IMM Medical Risk Application Questions
• How do age, sex, and mission duration affect the composition of 
medical system contents?
• What are the optimum medical system components that minimize risk 
(LOCL, EVAC) for a crew of six and mission duration of twelve months? 
• How does the composition of medical system contents change for a 
crew of six (four male, two female) for mission durations of four weeks, 
six months, twelve months, or three years to maintain a minimal risk 
posture? 
• What is the estimate of the in-flight functional impairment to the crew 
for a given level of care? 
• How is crew and mission risk affected by replacing one piece of 
hardware with the equivalent mass and volume of medications A, B, 
and C, and consumable items X, Y, and Z
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